Vinaver Medical: TissueXplorer platform, from scientific evidence to collaborative clinical research

Vinaver Medical has advanced TissueXplorer from a scientific concept into a vendor-agnostic platform for patient-specific stopping-power-ratio (SPR) mapping from spectral CT, now undergoing multi-centre clinical research. By deriving the tissue properties that determine proton interactions, TissueXplorer is designed to provide more direct information for particle-therapy treatment planning than conventional single-energy CT calibration. The platform also generates supporting density, effective atomic number, and iodine maps, and returns its outputs to existing clinical imaging and treatment-planning workflows without requiring new scanner hardware.

The scientific foundation was strengthened in 2026 by a peer-reviewed Medical Physics study of vendor-agnostic tissue characterization on a virtual photon-counting CT head scan. Patient-specific SPR estimation demonstrated the potential to substantially reduce CT-related proton range uncertainty compared with a conventional calibration approach, while preserving realistic patient anatomy and scanner physics.

The programme has since expanded beyond simulation into collaborative clinical research with New York Proton Center. Vinaver Medical’s network now spans several centers in the USA with first patient cohorts under evaluation. These studies are testing SPR and supporting quantitative outputs across different spectral CT technologies, institutional workflows, and clinically relevant anatomical sites. The team has also demonstrated integration in which processed maps are returned to PACS as standard CT series, allowing clinicians to review them using familiar tools.

The current focus is to deepen these collaborations and establish the clinical performance of patient-specific SPR mapping. Vinaver Medical welcomes discussions with particle therapy centres interested in contributing to this multi-vendor evidence base.